# Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue

> **NCT04496882** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **National Taiwan University Hospital** · enrollment: 260 (estimated)

## Conditions studied

- Chronic Hepatitis b
- Hepatitis B Reactivation

## Interventions

- **DRUG:** Vemlidy

## Key facts

- **NCT ID:** NCT04496882
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-09
- **Primary completion:** 2025-01-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2026-02-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04496882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04496882, "Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04496882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*